Issue Date: February 8, 2016
GSK And J&J Back Medicxi Fund
Life sciences venture capital firm Medicxi Ventures, recently spun off from Index Ventures, has closed a $250 million fund devoted to early-stage investments. GlaxoSmithKline and Johnson & Johnson have upped their stake in the fund, which is primarily focused on opportunities in Europe. Medicxi will continue Index’s “asset-centric” model, in which virtual companies are set up to develop a single therapy rather than a pipeline of drugs.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society